Entero Therapeutics, Inc. (NASDAQ:ENTO – Get Free Report)’s stock price shot up 6.3% on Monday . The company traded as high as $4.72 and last traded at $3.87. 618,995 shares were traded during trading, a decline of 78% from the average session volume of 2,798,922 shares. The stock had previously closed at $3.64.
Entero Therapeutics Trading Up 1.9%
The business’s 50-day moving average is $2.50 and its two-hundred day moving average is $2.95. The firm has a market cap of $6.11 million, a P/E ratio of -2.28 and a beta of 1.19.
Institutional Investors Weigh In On Entero Therapeutics
An institutional investor recently bought a new position in Entero Therapeutics stock. Virtu Financial LLC acquired a new stake in shares of Entero Therapeutics, Inc. (NASDAQ:ENTO – Free Report) in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,829 shares of the company’s stock, valued at approximately $59,000. Virtu Financial LLC owned about 0.74% of Entero Therapeutics as of its most recent SEC filing. 12.30% of the stock is currently owned by hedge funds and other institutional investors.
Entero Therapeutics Company Profile
Entero Therapeutics, Inc (NASDAQ: ENTO) is a clinical‐stage specialty pharmaceutical company dedicated to developing innovative therapies for patients suffering from rare and debilitating gastrointestinal (GI) disorders. The company leverages targeted delivery technologies designed to localize therapeutic molecules directly to affected regions of the GI tract, aiming to enhance efficacy while minimizing systemic exposure. Entero’s research and development efforts focus on addressing chronic conditions with significant unmet medical needs, including malabsorption syndromes and motility‐related GI diseases.
Entero’s pipeline features multiple lead candidates in varying stages of clinical development.
Read More
- Five stocks we like better than Entero Therapeutics
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
- AI Consolidation Begins: Blackstone & Google Forge an AI Empire
- USA Rare Earth Posts Strong Q1 2026 as Massive Serra Vera Deal Looms
- 3 Space Infrastructure Stocks Gaining Momentum Ahead of the SpaceX IPO
Receive News & Ratings for Entero Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Entero Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
